Pages that link to "Q44602385"
Jump to navigation
Jump to search
The following pages link to Reasons for Early Abacavir Discontinuation in HIV-Infected Patients (Q44602385):
Displaying 14 items.
- Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function. (Q33207117) (← links)
- Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics (Q36081993) (← links)
- Emerging anti-HIV drugs (Q36150601) (← links)
- Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again (Q36341730) (← links)
- Pharmacogenetic information derived from analysis of HLA alleles (Q37120841) (← links)
- Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant (Q37356747) (← links)
- Successful translation of pharmacogenetics into the clinic: the abacavir example (Q37436365) (← links)
- HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects (Q37514235) (← links)
- Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. (Q37768070) (← links)
- Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome (Q38122461) (← links)
- Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele (Q40381501) (← links)
- Comment: Reasons for early abacavir discontinuation in HIV-infected patients (Q44741672) (← links)
- HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance (Q46445494) (← links)
- Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity. (Q53135190) (← links)